Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study. Issue 3 (May 2015)

• Record Type: Journal Article
• Authors: Robert, Sarah Anne; Rohana, Abdul Ghani; Shah, Shamsul Azhar; Chinna, Karuthan; Wan Mohamud, Wan Nazaimoon; Kamaruddin, Nor Azmi
• Is Part Of: Obesity research & clinical practice. Volume 9:Issue 3(2015:May/Jun.)
• Page Start: 301
• Page End: 304
• Publication Date: 2015-05
• Subjects: Obesity -- Research -- Periodicals; Obesity -- Treatment -- Periodicals; Obesity -- Periodicals; Obésité -- Recherche -- Périodiques; Obésité -- Traitement -- Périodiques; Obesity -- Research; Obesity -- Treatment; Electronic journals; Periodicals; 616.398
• DOI: 10.1016/j.orcp.2015.03.005
• Languages: English
• ISSNs: 1871-403X

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Summary</title> <sec> <p id="spar0005">We examined the effects of liraglutide, a glucagon-like peptide-1 analogue on appetite and plasma ghrelin in non-diabetic obese participants with subclinical binge eating (BE). Forty-four obese BE participants (mean age: 34 ± 9 years, BMI: 35.9 ± 4.2 kg/m²) were randomly assigned to intervention or control groups for 12 weeks. All participants received standard advice for diet and exercise. Binge eating score, ghrelin levels and other anthropometric variables were evaluated at baseline and at the end of the study. Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol. Ghrelin levels were significantly increased which may potentially diminish the weight loss effects of liraglutide beyond the intervention.</p> </sec> </abstract>